Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent.

Accardo A, Salsano G, Morisco A, Aurilio M, Parisi A, Maione F, Cicala C, Tesauro D, Aloj L, De Rosa G, Morelli G.

Int J Nanomedicine. 2012;7:2007-17. doi: 10.2147/IJN.S29242. Epub 2012 Apr 17.

2.

Bombesin peptide antagonist for target-selective delivery of liposomal doxorubicin on cancer cells.

Accardo A, Mansi R, Salzano G, Morisco A, Aurilio M, Parisi A, Maione F, Cicala C, Ziaco B, Tesauro D, Aloj L, De Rosa G, Morelli G.

J Drug Target. 2012 Nov 21. [Epub ahead of print]

PMID:
23167653
3.

In vitro demonstration of enhanced prostate cancer toxicity: pretargeting with Bombesin bispecific complexes and targeting with polymer-drug-conjugates.

Patil V, Gada K, Panwar R, Majewski S, Tekabe Y, Varvarigou A, Khaw BA.

J Drug Target. 2013 Dec;21(10):1012-21. doi: 10.3109/1061186X.2013.818675. Epub 2013 Jul 18.

PMID:
23863118
4.

Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice.

Ho CL, Chen LC, Lee WC, Chiu SP, Hsu WC, Wu YH, Yeh CH, Stabin MG, Jan ML, Lin WJ, Lee TW, Chang CH.

Cancer Biother Radiopharm. 2009 Aug;24(4):435-43. doi: 10.1089/cbr.2008.0616.

PMID:
19694578
5.

Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.

Teymouri M, Badiee A, Golmohammadzadeh S, Sadri K, Akhtari J, Mellat M, Nikpoor AR, Jaafari MR.

Int J Pharm. 2016 Sep 10;511(1):236-44. doi: 10.1016/j.ijpharm.2016.06.117. Epub 2016 Jun 27.

PMID:
27363937
6.

Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.

Chen X, Wang X, Wang Y, Yang L, Hu J, Xiao W, Fu A, Cai L, Li X, Ye X, Liu Y, Wu W, Shao X, Mao Y, Wei Y, Chen L.

J Control Release. 2010 Jul 1;145(1):17-25. doi: 10.1016/j.jconrel.2010.03.007. Epub 2010 Mar 20.

PMID:
20307599
7.

Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers.

Wang C, Sun X, Wang K, Wang Y, Yang F, Wang H.

Drug Deliv. 2016 Oct;23(8):2697-2702. Epub 2015 Jul 23.

PMID:
26203692
8.

Design, preparation, in vitro and in vivo evaluation of (99m)Tc-N2S2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical.

Santos-Cuevas CL, Ferro-Flores G, Arteaga de Murphy C, Ramírez Fde M, Luna-Gutiérrez MA, Pedraza-López M, García-Becerra R, Ordaz-Rosado D.

Int J Pharm. 2009 Jun 22;375(1-2):75-83. doi: 10.1016/j.ijpharm.2009.04.018. Epub 2009 Apr 22.

PMID:
19393305
9.

Target selective micelles for bombesin receptors incorporating Au(III)-dithiocarbamato complexes.

Ringhieri P, Iannitti R, Nardon C, Palumbo R, Fregona D, Morelli G, Accardo A.

Int J Pharm. 2014 Oct 1;473(1-2):194-202. doi: 10.1016/j.ijpharm.2014.07.014. Epub 2014 Jul 8.

PMID:
25014371
11.
12.
13.

In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215.

Plonowski A, Nagy A, Schally AV, Sun B, Groot K, Halmos G.

Int J Cancer. 2000 Nov 15;88(4):652-7.

14.

Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.

Kahán Z, Sun B, Schally AV, Arencibia JM, Cai RZ, Groot K, Halmos G.

Cancer. 2000 Mar 15;88(6):1384-92.

PMID:
10717621
15.

Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.

Jungwirth A, Galvan G, Pinski J, Halmos G, Szepeshazi K, Cai RZ, Groot K, Schally AV.

Prostate. 1997 Aug 1;32(3):164-72.

PMID:
9254895
16.

Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.

Szepeshazi K, Schally AV, Rick FG, Block NL, Vidaurre I, Halmos G, Szalontay L.

Anticancer Drugs. 2012 Oct;23(9):906-13. doi: 10.1097/CAD.0b013e328354bd25.

PMID:
22926257
17.
18.

Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells.

Morisco A, Accardo A, Tesauro D, Palumbo R, Benedetti E, Morelli G.

Biopolymers. 2011;96(1):88-96. doi: 10.1002/bip.21491.

PMID:
20560147
19.

In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer.

Craft JM, De Silva RA, Lears KA, Andrews R, Liang K, Achilefu S, Rogers BE.

Nucl Med Biol. 2012 Jul;39(5):609-16. doi: 10.1016/j.nucmedbio.2011.12.004. Epub 2012 Jan 20.

20.

The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo.

Wang C, Wang X, Zhong T, Zhao Y, Zhang WQ, Ren W, Huang D, Zhang S, Guo Y, Yao X, Tang YQ, Zhang X, Zhang Q.

Int J Nanomedicine. 2015 Mar 19;10:2229-48. doi: 10.2147/IJN.S79840. eCollection 2015.

Supplemental Content

Support Center